Navlimetostat

Navlimetostat (BMS-986504, MRTX1719) is a small-molecule drug developed by Bristol-Myers Squibb. Its target is PRMT5 (MTAP-deleted cancers) (the sponsor names PRMT5 (protein arginine methyltransferase 5)). The sponsor states: Navlimetostat (BMS-986504) is a selective MTA-cooperative inhibitor of PRMT5, studied in participants with homozygous MTAP deletion. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07063745 (A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion) and NCT07076121 (A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)), in non-small-cell lung cancer and pancreatic ductal adenocarcinoma. The largest, NCT07063745, plans to enrol 590 participants with primary completion expected 2031-08-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.